Ron Peters in conversation with Ulf Landmesser
RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial.
Sanjit Jolly in conversation with Thomas Lüscher
FUTURA OASIS 8 : A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux.
Jens Nielsen In conversation with Thomas Lüscher
DANPACE: The Danish multicentre randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome.
Bernard Gersh In conversation with Thomas Lüscher
The management of hypertrophic cardiomyopathy: evidence and uncertainties.
John McMurray In conversation with Frank Ruschitzka
TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy.
Andreas Goette In conversation with Bernard Gersh
ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial.
Stefanie Schulz in conversation with Ulf Landmesser
ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions.
Sunil Rao in conversation with Thomas Lüscher
INNOVATE PCI: A Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibtor in Non-Urgent PCI.
Stuart Connolly in conversation with Thomas Lüscher
AVERROES: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Strokes.
Adriaan Voors in a conversation with Thomas Lüscher
HEBE III: A single dose of erhthropoietin in ST-elevation myocardial infarction.